Idelara

Idelara

letrozole

Manufacturer:

Craveri

Distributor:

Apolloplus Capital

Marketer:

Bioprofarma Bago
Concise Prescribing Info
Contents
Letrozole
Indications/Uses
Adjuvant treatment of postmenopausal women w/ hormone receptor +ve early breast cancer. Extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. 1st-line treatment of postmenopausal women w/ hormone receptor +ve or unknown locally advanced or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ disease progression following antiestrogen therapy.
Dosage/Direction for Use
Adult & elderly 2.5 mg once daily. Severe hepatic impairment 2.5 mg every other day.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Premenopausal endocrine status.
Special Precautions
Monitor BMD. May affect driving or using machinery. Pregnancy & lactation. Childn.
Adverse Reactions
Adjuvant treatment of early breast cancer in postmenopausal women: Fractures, MI & arthralgia. Extended adjuvant treatment of early breast cancer in postmenopausal women: Hot flashes, arthralgia/arthritis & myalgia. 1st-line breast cancer: Bone pain, hot flushes, back pain, nausea, arthralgia & dyspnea. 1st-line & 2nd-line breast cancer: Cataract, eye irritation, palpitations, cardiac failure, tachycardia, dysesthesia, arterial thrombosis, memory impairment, irritability, nervousness, urticaria, increased urinary frequency, leukopenia, stomatitis, cancer pain, pyrexia, vag discharge, increased appetite, dryness of skin & mucosa, disturbances of taste & thirst.
ATC Classification
L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Presentation/Packing
Form
Idelara FC tab 2.5 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in